{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:01:10Z","timestamp":1793275270710,"version":"4.5.0"},"reference-count":29,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2014,5,27]],"date-time":"2014-05-27T00:00:00Z","timestamp":1401148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Blocking metabotropic glutamate receptor type 5 (mGluR5) has been proposed as a target for levodopa\u2010induced dyskinesias (LID) in Parkinson's disease (PD). We assessed the effect on LID of dipraglurant, a potent selective mGluR5 receptor negative allosteric modulator in the gold\u2010standard LID macaque model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Dipraglurant (3, 10, and 30 mg\/kg, by mouth) was tested in the 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine (MPTP) macaque model of LID in a four\u2010way crossover, single\u2010dose, controlled study (n\u2009=\u20098).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Dipraglurant inhibited dyskinesias in the LID macaque model, with best effect reached at 30 mg\/kg dose with no alteration of levodopa efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Acute challenges of dipraglurant were efficacious on choreic and dystonic LID in the MPTP\u2010macaque model. Dipraglurant pharmacokinetic variables were similar to those of levodopa, suggesting that both drugs can be co\u2010administered simultaneously in further studies. \u00a9 2014 International Parkinson and Movement Disorder Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/mds.25920","type":"journal-article","created":{"date-parts":[[2014,5,27]],"date-time":"2014-05-27T14:12:31Z","timestamp":1401199951000},"page":"1074-1079","source":"Crossref","is-referenced-by-count":77,"title":["The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model"],"prefix":"10.1002","volume":"29","author":[{"given":"Erwan","family":"Bezard","sequence":"first","affiliation":[{"name":"Motac neuroscience Manchester UK"},{"name":"Universit\u00e9 de Bordeaux Institut des Maladies Neurod\u00e9g\u00e9n\u00e9ratives, UMR 5293 Bordeaux France"},{"name":"CNRS Institut des Maladies Neurod\u00e9g\u00e9n\u00e9ratives, UMR 5293 Bordeaux France"},{"name":"Service de Neurologie CHU de Bordeaux Pessac France"},{"name":"Institute of Laboratory Animal Sciences China Academy of Medical Sciences Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa Y.","family":"Pioli","sequence":"additional","affiliation":[{"name":"Motac neuroscience Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[{"name":"Motac neuroscience Manchester UK"},{"name":"Institute of Laboratory Animal Sciences China Academy of Medical Sciences Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Girard","sequence":"additional","affiliation":[{"name":"Addex Pharma SA Plan Les Ouates  Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Mutel","sequence":"additional","affiliation":[{"name":"Addex Pharma SA Plan Les Ouates  Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Keywood","sequence":"additional","affiliation":[{"name":"Addex Pharma SA Plan Les Ouates  Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Tison","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Bordeaux Institut des Maladies Neurod\u00e9g\u00e9n\u00e9ratives, UMR 5293 Bordeaux France"},{"name":"CNRS Institut des Maladies Neurod\u00e9g\u00e9n\u00e9ratives, UMR 5293 Bordeaux France"},{"name":"Service de Neurologie CHU de Bordeaux Pessac France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[{"name":"CIC Toulouse  France"},{"name":"D\u00e9partements de Pharmacologie Clinique et Neurosciences INSERM CIC9302 CHU de Toulouse France"},{"name":"Service de Pharmacologie Facult\u00e9 de M\u00e9decine, CHU de Toulouse, Universit\u00e9 de Toulouse  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia M.","family":"Poli","sequence":"additional","affiliation":[{"name":"Addex Pharma SA Plan Les Ouates  Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,5,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2005.01096.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2010.05.001"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2005.12.009"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2007.08.011"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.04456.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2009.07.060"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2011.01.008"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.166629"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2009.12.024"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23616"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000664"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20296"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm875"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1012071107"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000664"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20296"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm875"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1012071107"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59426"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn235"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25133"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.14-05-03005.1994"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2004.09.005"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2004.07.005"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2009.07.014"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.150425"},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.1523\/JNEUROSCI.23-23-08302.2003","article-title":"Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal\u2010ganglia structures in parkinsonian rats","volume":"23","author":"Breysse N","year":"2003","journal-title":"J Neurosci"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.25920","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.25920","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.25920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:36:02Z","timestamp":1760956562000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.25920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,27]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1002\/mds.25920"],"URL":"https:\/\/doi.org\/10.1002\/mds.25920","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,27]]}}}